Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oculis Holding AG
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
August 24, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
August 10, 2026
Oculis Reports Q2 2026 Financial Results and Provides Company Update
August 6, 2026
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
August 3, 2026
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
May 22, 2026
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 21, 2026
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 20, 2026
Oculis to Participate in Upcoming Investor Conferences
April 7, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
1
2
Next Page
→